Evolution of Molecular Testing and a Review of Mayo's New Solid Tumor Comprehensive Genomic Profiling


Virtual Lecture

Expires: April 20, 2024

Overview

In this month's "Virtual Lecture," Kevin Halling, M.D., Ph.D., discusses the evolution of clinical laboratory molecular testing over the past 40 years and the types of alterations that are detected by solid tumor comprehensive genomic profiling. He also summarizes the clinical utility of solid tumor comprehensive genomic profiling.

Presentation

Length of Video: 52 minutes

Presenter

Kevin Halling, M.D., Ph.D.

Professor of Laboratory Medicine and Pathology
Division of Laboratory Genetics and Genomics
Mayo Clinic, Rochester, Minnesota

Learning objectives

Upon completion of this activity, participants should be able to:

  • Describe the evolution of clinical laboratory molecular testing over the past 40 years.
  • Discuss the types of alterations that are detected by solid tumor comprehensive genomic profiling.
  • Summarize the clinical utility of solid tumor comprehensive genomic profiling.

Intended audience

This program is appropriate for clinicians, pathologists, medical technologists, nurses, pharmacists, and other allied health staff.

Credit

The following types of credit are offered for this event:

ASCLS P.A.C.E.®

Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of 1.0 P.A.C.E.® contact hour.

State of Florida

Mayo Clinic Laboratories is approved as a Continuing Education Accrediting Agency for the Clinical Laboratory Sciences for the State of Florida. Florida Board of Clinical Laboratory Personnel has designated this program for General credit. This program has been approved for 1.0 contact hour.

To obtain credit


1. Watch the video.

2. Complete the post-test and evaluation that launches immediately following the video.

3. Generate and print your certificate(s).

Level of instruction for this program is intermediate.

Faculty disclosure


Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.

Questions?

Contact us: mcleducation@mayo.edu

Image credit: Shutterstock

MCL Education

This post was developed by our Education and Technical Publications Team.